New drug duo tested in Tough-to-Treat esophageal cancer

NCT ID NCT06753747

Summary

This study is testing whether combining two existing drugs, afatinib and palbociclib, can help control advanced esophageal cancer that has come back or spread after prior treatment. The first part of the trial will find a safe dose, and the second part will see if the combination can shrink tumors in up to 45 patients. The goal is to see if this new approach can offer a new option for people who have run out of standard treatments.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGUS CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • West China Hospital

    RECRUITING

    Chengdu, Sichuan, 610041, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.